The #ALS space—and the HEALEY ALS Platform Trial—saw two more failures this week, from Denali Therapeutics and AbbVie/Calico Life Sciences. After a disappointing 2024 for the space ...
Zacks.com on MSN2d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
The multi-centre, placebo-controlled, double-blind trial will assess the therapy’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients. Sean M Healey & AMG Centre for ...
GlobalData on MSN3d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatmentThe US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...
failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price. The South San Francisco biotech announced that eIF2B agonist DNL343 was unable to slow ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
The agreement, signed Friday on one of the last days of the Biden administration, reduces the total cost owed to the federal government by about $1 billion The Healey administration has reached a ...
Like a magician, Governor Maura Healey pulled a rabbit out of her hat this week with her task force on transportation funding. Healey formed the task force in January 2024 to come up with “a ...
Rep. Marcus Vaughn, a Wrentham Republican, laid out the grim outline in response to Gov. Maura Healey’s second State of the Commonwealth address, which she used to largely reflect on her ...
Drawing from Massachusetts history while also peeking into the future, Gov. Maura Healey on Thursday night took stock of the state's strengths and challenges in a speech that focused more on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback